Clinical Trial Update: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial of Descartes-15 for relapsed or refractory multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Descartes-15

Snippet

Sponsor: Cartesian Therapeutics | Conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma | Phase 1 | Status: TERMINATED